ProStrakan begins European roll-out for granisetron patch
This article was originally published in Scrip
ProStrakan, the UK-based subsidiary of Kyowa Hakko Kirin, has finally started the EU roll-out of its transdermal granisetron patch, Sancuso, for the prevention of chemotherapy-induced nausea and vomiting.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.